RETRACTED ARTICLE: Recent advances on applications of immunosensing systems based on nanomaterials for CA15-3 breast cancer biomarker detection

MoS2-ZnO Nanocomposite Mediated Immunosensor for Non-Invasive Electrochemical Detection of IL8 Oral Tumor Biomarker

In order to support biomolecule attachment, an effective electrochemical transducer matrix for biosensing devices needs to have many specialized properties, including quick electron transfer, stability, high surface area, biocompatibility, and the presence of particular functional groups. Enzyme-linked immunosorbent assays, gel electrophoresis, mass spectrometry, fluorescence spectroscopy, and surface-enhanced Raman spectroscopy are common techniques used to assess biomarkers. Even though these techniques provide precise and trustworthy results, they cannot replace clinical applications because of factors such as detection time, sample amount, sensitivity, equipment expense, and the need for highly skilled individuals. For the very sensitive and targeted electrochemical detection of the salivary oral cancer biomarker IL8, we have created a flower-structured molybdenum disulfide-decorated zinc oxide composite on GCE (interleu-kin-8). This immunosensor shows very fast detection; the limit of detection (LOD) for interleukin-8 (IL8) detection in a 0.1 M phosphate buffer solution (PBS) was discovered to be 11.6 fM, while the MoS₂/ZnO nanocomposite modified glassy carbon electrode (GCE) demonstrated a high catalytic current linearly from 500 pg to 4500 pg mL^-1 interleukin-8 (IL8). Therefore, the proposed biosensor exhibits excellent stability, high accuracy sensitivity, repeatability, and reproducibility and shows the acceptable fabrication of the electrochemical biosensors to detect the ACh in real sample analysis.

Recent Progress in Biosensors for Detection of Tumor Biomarkers

Cancer is a leading cause of death worldwide, with an increasing mortality rate over the past years. The early detection of cancer contributes to early diagnosis and subsequent treatment. How to detect early cancer has become one of the hot research directions of cancer. Tumor biomarkers, biochemical parameters for reflecting cancer occurrence and progression have caused much attention in cancer early detection. Due to high sensitivity, convenience and low cost, biosensors have been largely developed to detect tumor biomarkers. This review describes the application of various biosensors in detecting tumor markers. Firstly, several typical tumor makers, such as neuron-specific enolase (NSE), carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), squamous cell carcinoma antigen (SCCA), carbohydrate, antigen19-9 (CA19-9) and tumor suppressor p53 (TP53), which may be helpful for early cancer detection in the clinic, are briefly described. Then, various biosensors, mainly focusing on electrochemical biosensors, optical biosensors, photoelectrochemical biosensors, piezoelectric biosensors and aptamer sensors, are discussed. Specifically, the operation principles of biosensors, nanomaterials used in biosensors and the application of biosensors in tumor marker detection have been comprehensively reviewed and provided. Lastly, the challenges and prospects for developing effective biosensors for early cancer diagnosis are discussed.

Point-of-care electrochemical testing of biomarkers involved in inflammatory and inflammatory-associated medical conditions

Recent years have shown that the diagnosis and monitoring of biomarkers involved in inflammatory-associated medical conditions such as cancer, neurological disorders, viral infections, or daily physical activities offer real benefits in increasing the quality of medical care and patient life quality. In this context, the use of integrated and portable platforms as point-of-care testing devices for biomedical analysis to enable early disease diagnosis and monitoring, which can be successfully used even at the patient's bed, is an emergency nowadays. The development of low-cost, miniaturized, and portable, user-friendly devices that provide an answer in a timely manner, such as electrochemical sensors, is relevant for the elaboration of point-of-care testing devices. This review focuses on the recent progress in bioanalysis of both specific biomarkers and inflammatory-associated biomarkers present in several diseases like neoplasia, severe neurological disorders, viral infections, and usual physical activity and provides an overview of the state of the art over the most recent electrochemical (bio)sensors for the detection of inflammation-related biomarkers. Future perspectives of point-of-care testing to improve healthcare management are also discussed.

Carbon Nanopowder-Based Stochastic Sensor for Ultrasensitive Assay of CA 15-3, CEA and HER2 in Whole Blood

Two microsensors obtained by the physical immobilization of 5,10,15,20-tetraphenyl-21H,23H-porphine (TPP) and 5,10,15,20-tetrakis (pentafluorophenyl chloride)-21H,23H-iron (III) porphyrin (Fe(TPFPP)Cl) in carbon nanopowder decorated with gold nanoparticles (AuNp) were designed, characterized, validated and used for the molecular recognition and simultaneous ultrasensitive determination of CEA, CA15-3 and HER2 in whole blood. High sensitivities were recorded for both microsensors. Low limits of quantification were recorded for all biomarkers: CEA (12.8 pg mL-1 by using Fe(TPFPP)Cl/AuNp, and 190 fg mL-1 by using TPP/AuNp), CA 15-3 (100 fU mL-1 for both microsensors) and HER2 (3.9 fg mL-1 by using Fe(TPFPP)Cl/AuNp, and 35 fg mL-1 by using TPP/AuNp). A very good correlation between the results obtained using the proposed microsensors and ELISA, certified by the Student t-test, proves that the screening test can be used for ultrasensitive assays of the three biomarkers in whole blood.